China has one of the world’s most complicated and regulated healthcare industries. It still takes at least two years for most drugs and medical devices to obtain the necessary licenses to be sold nationwide. Furthermore, the new wave of healthcare reforms initiated in 2015 will add to the existing imposing regulatory environment, greatly impacting the profitability and attractiveness of the Chinese healthcare market. In this op-ed piece, Jelte Wingender, Manager at Solidiance who heads up the Beijing office, gives insights on China’s cardiovascular drug and device market and the outcome of their healthcare reforms.


Download the article (PDF)